Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
The investigators performed a multi-centered, randomized, double blinded, placebo-controlled,
prospective clinical trial on the effect of Yiqi-yangyin-jiedu decoction (YYJD), a chinese
herbal medicine (CHM) formula combined with gefitinib to prolong the progression free
survival (PFS) of advanced pulmonary adenocarcinoma patients with activating EGFR mutation
(exon19del or exon21L858R). The investigators plan to enroll 198 cases in 3 years (99 cases
for gefitinib, 99 cases for gefitinib plus YYJD), expecting that combination therapy has a
better efficacy on prolonging PFS, overall survival, improving quality of life(QOL).
Phase:
Phase 3
Details
Lead Sponsor:
Shanghai University of Traditional Chinese Medicine
Collaborators:
Shanghai Chest Hospital Shanghai Pulmonary Hospital, Shanghai, China